Stocks and Investing Stocks and Investing
Tue, September 25, 2018
Mon, September 24, 2018
Fri, September 21, 2018
Thu, September 20, 2018
Wed, September 19, 2018
Tue, September 18, 2018
Mon, September 17, 2018
Fri, September 14, 2018
Thu, September 13, 2018

Paul Matteis Maintained (ALNY) at Strong Buy with Decreased Target to $117 on, Sep 13th, 2018


Published on 2024-10-26 08:40:42 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy with Decreased Target from $123 to $117 on, Sep 13th, 2018.

Paul has made no other calls on ALNY in the last 4 months.



There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $93 on, Monday, August 13th, 2018


These are the ratings of the 5 analyists that currently disagree with Paul


  • Christopher Marai of "Nomura" Maintained at Sell with Decreased Target to $73 on, Monday, August 13th, 2018
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $125 on, Monday, August 13th, 2018
  • Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $230 on, Monday, August 13th, 2018
  • Ritu Baral of "Cowen & Co." Maintained at Buy with Decreased Target to $147 on, Monday, August 13th, 2018
  • Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $123 on, Monday, August 13th, 2018